Advertisement

Belatacept

  • Giuseppe TridenteEmail author
Chapter

Abstract

Belatacept (Nulojix®, Brystol-Meyers Squibb) is a fusion protein binding to CD80 and CD86, thus blocking their interaction with CD28 receptor and the consequent costimulatory signal to activate T lymphocytes.

Keywords

Treg Cell West Nile Virus Progressive Multifocal Leukoencephalopathy Cryptococcal Meningitis Progressive Multifocal Leukoencephalopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_44_MOESM1_ESM.xls (55 kb)
Supplementary material 1 (XLS 56 kb)

References

  1. 1.
    Belatacept (Nulojix®) BLA125288 Medical Review FDA, June 2011Google Scholar
  2. 2.
    Belatacept (Nulojix®) WC500108357 CHMP Assessment Report EMEA Apr 2011Google Scholar
  3. 3.
    Belatacept (Nulojix®) Prescribing Information BMS, June 2011Google Scholar
  4. 4.
    Belatacept (Nulojix®) WC500108355 Product Information EMEA, Sept 2011Google Scholar
  5. 5.
    Belatacept (Nulojix®) R 179687 Australian Public Assessment Report, TGA July 2012Google Scholar
  6. 6.
    Gupta G, Womer KL (2010) Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation. Drug Design Develop Ther 4:375–382Google Scholar
  7. 7.
    Wojciechowski D, Vincenti F (2012) Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update. Biol Targets Ther 6:39–385Google Scholar
  8. 8.
    Grinyo J, Alberu J, Contieri FLC et al (2012) Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. Transplant Intern 25:1059–1064CrossRefGoogle Scholar
  9. 9.
    Zhou Z, Shen J, Hong Y et al (2012) Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. Clin Pharmacol Ther 92:251–257PubMedCrossRefGoogle Scholar
  10. 10.
    Soveri I, Snyder J, Holdaas H et al (2013) The external validation of the cardiovascular risk equation for renal transplant recipients: applications to BENEFIT and BENEFIT-EXT trials. Transplantation 95:142–147PubMedCrossRefGoogle Scholar
  11. 11.
    Grinyo JM, Budde K, Citterio F et al (2013) Belatacept utilization recommendations: an expert position. Expert Opin Drug Saf 12:111–122PubMedCrossRefGoogle Scholar
  12. 12.
    Archdeacon P, Dixon C, Belen O et al (2012) Summary of the US FDA approval of belatacept. Am J Tranpl 12:554–662Google Scholar
  13. 13.
    Lo DJ, Anderson DJ, Weaver TA et al (2013) Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T Cell depletion. Am J Transpl 13:320–328CrossRefGoogle Scholar
  14. 14.
    Malzman JS (2012) Costimulatory blockade—A double-edged sword? Amer J Tranplant 12:2269–2270CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations